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a b s t r a c t
A role for the beta genus HPVs in keratinocyte carcinoma (KC) remains to be established. In this article
we examine the potential role of the beta HPVs in cancer revealed by the epidemiology associating these
viruses with KC and supported by oncogenic properties of the beta HPV proteins. Unlike the cancer
associated alpha genus HPVs, in which transcriptionally active viral genomes are invariably found
associated with the cancers, that is not the case for the beta genus HPVs and keratinocyte carcinomas.
Thus a role for the beta HPVs in KC would necessarily be in the carcinogenesis initiation and not in the
maintenance of the tumor.
& 2015 Elsevier Inc. All rights reserved.
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Introduction
The papillomaviridae family comprises approximately 200
different human papillomavirus (HPV) types, which are clustered
among the ﬁve genera alpha, beta, gamma, mu, and nu (www.
hpvcenter.se/html/refclones.html). Among the genus alpha HPV
types are those that induce benign, non-genital skin warts, the
low-risk mucosotropic HPVs that induce genital warts and laryn-
geal papillomas, and the high-risk mucosotropic HPVs that are
associated with cervical cancer, other anogenital cancers and
oropharyngeal cancers (Howley et al., 2013).
Genus beta HPV were ﬁrst identiﬁed in ﬂat warts and macular,
red, brown, or achromic lesions as well as cutaneous squamous cell
carcinomas (SCC) of patients with the rare disease epidermodysplasia
verruciformis (EV) and were initially referred to as EV-HPVs. Cuta-
neous SCC arise in 30–60% of EV-patients during the second to fourth
decade of life, 10–30 years after the onset of benign skin lesions.
Cancers are frequently localized in sun-exposed areas of the skin
(Orth, 1986). SCC in EV harbor multiple genome copies of speciﬁc
HPV types, especially HPV5 and HPV8 but also HPV14, HPV20, and a
few others (de Oliveira et al., 2004; Dell'Oste et al., 2009; Orth, 1986).
Viral transcripts have been described in several of these EV-
associated SCCs (reviewed in Pﬁster and Ter Schegget (1997)). In
2009, HPV5 and HPV8 were classiﬁed by IARC as “possibly carcino-
genic” in EV patients (Bouvard et al., 2009).
The oncogenic potential of some of the beta HPV types (described
below) and the consistent ﬁnding of certain beta genus HPV types in
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EV-associated SCC make HPV an attractive etiologic agent for at least
some SCCs in individuals who do not have EV (Feltkamp et al., 2008).
In the general population, the prevalence of beta HPV-DNA in cutane-
ous SCC is lower than in EV. In contrast to EV, a diverse spectrum of
beta HPV types has been detected and no single types predominate. In
those positive tumors, the viral load in tumor biopsies is less than one
genome per cell (Weissenborn et al., 2005). In addition, transcriptome
sequencing failed to identify papillomavirus expression in any of non-
EV associated SCCs indicating that beta HPV is not active in cutaneous
SCC (Arron et al., 2011). Thus, in contrast to the alpha genus HPV-
associated cancers where transcriptionally active HPV DNA is required
for tumor maintenance, the presence of a beta HPV is obviously not
mandatory for maintenance of themalignant phenotype in SCCs in the
general population. Thus if any of the beta HPVs are associated with
SCCs in the general population, their role must be in the initiation of
the cancer rather than its maintenance. The prevalence of beta HPV-
DNA in precancerous actinic keratosis is higher than in SCCs and
higher HPV-DNA loads (up to 50 copies/cell) are compatible with a
carcinogenic role of the beta HPVs in early phases of skin cancer
development (Weissenborn et al., 2005). Active replication and
expression of beta HPVs has been demonstrated in actinic keratosis
lesions as well as in the adjacent pathological epithelium of SCCs in
renal transplant patients, where beta HPV expression is also associated
with increased expression of the cellular proliferation marker MCM7
(Borgogna et al., 2014).
Epidemiology of beta HPV infections
The signiﬁcance of the association of the beta HPVs and skin
cancer is challenged somewhat since these HPV types are ubiqui-
tous and infect the skin of all people as a commensal ﬂora. More
than 80% of healthy donors were positive for beta HPV DNA in skin
swabs or plucked eyebrow hairs where many different beta HPV
types are frequently observed (Antonsson et al., 2000; de Koning
et al., 2009). HPV positivity can be demonstrated soon after birth
(Antonsson et al., 2003; Weissenborn et al., 2009). The hair follicle
is regarded as the natural reservoir for the cutaneous beta HPVs.
HPV is present in hair follicles from different body sites such as
scalp, eyebrow, arm, trunk, leg, and pubic region (Köhler et al.,
2007). The beta HPV type spectrum in eyebrow hair follicles is to a
signiﬁcant degree representative of different body sites suggesting
generalized infection of the entire skin. Eyebrow hairs have
therefore served as easily collected marker in many recent
epidemiological studies (Plasmeijer et al., 2010).
Case control studies of SCC examining beta HPV-DNA and/or
serum antibody have revealed moderate odds ratios in the range of
1.5–2.8 with lower 95% conﬁdence interval limits between 1.0 and
1.4 (Bouwes Bavinck et al., 2010; Karagas et al., 2006; Struijk et al.,
2003). To assess beta HPV expression serum samples were mostly
analyzed for antibodies to the major capsid protein L1. More
recently, multiplex serology was used, which allows the simulta-
neous detection of antibodies against more than 15 beta HPV types.
A prospective pilot study based on the prevalence of serum
antibodies failed to reveal differences between cases and controls
in blood samples taken more than 18 months prior to diagnosis of
SCC (Casabonne et al., 2007). This was interpreted to suggest that
the antibody response observed in people with SCC is a conse-
quence of tumor formation rather than evidence for previous viral
activity and resulted in an IARC working group in 2009 to consider
the beta HPVs as not classiﬁable as to their carcinogenicity in
humans (Bouvard et al., 2009). However, this conclusion may not be
valid since seroconversion after beta HPV infections has been
shown to be extremely slow, occuring years or even decades after
initial contact (Michael et al., 2008). Persistent beta HPV infection,
as such, may only poorly drive serologic responses without addi-
tional “danger” signals such as local inﬂammation or tumor growth.
This could explain that an association with beta HPV seropositivity
became only obvious rather late in individuals with prevalent
tumors or less than 18 months prior to diagnosis of SCC
(Casabonne et al., 2007). Earlier critical viral activities are not
excluded by seronegativity. It is highly interesting that beta HPV
seropositivity around transplantation implied a hazard ratio of
2.8 to develop KC in organ transplant recipients, who were followed
for up to 22 years (Genders et al., 2014).
Recent natural history studies of beta HPV infections have
emphasized that the prevalent beta HPVs should be differentiated
into types that are transiently detectable and those that persist,
with the belief that the beta HPV types that result in persistent
infections are more likely to have pathological consequences.
Studies of intrafamilial transmission revealed a majority of fre-
quently exchanged beta HPV types and a minority of persisting
Fig. 1. Genus beta type-speciﬁc DNA loads in plucked eyebrow hairs of controls and SCC cases who were concordant for a single HPV type in their eyebrow hair and tumor
tissue. Controls had a single HPV type in their eyebrow hair that was the same detected in the SCC cases. Fully colored bars show the result of quantitative PCR. Partially
colored bars represent quantitative PCR negative but qualitative PCR positive samples with the height giving the threshold of detection of quantitative PCR (Iannacone et al.,
2014).
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beta HPV types among individuals (Hsu et al., 2009; Weissenborn
et al., 2009). The grouping together of the beta HPV types
regardless of whether or not they can cause persistent infections
has potentially masked differences among different beta HPV
types and has undoubtedly signiﬁcantly handicapped epidemio-
logic case control studies. Although more recent epidemiologic
studies have tried to focus on the biologically more relevant beta
HPV infections, it is still uncertain, which parameters best reﬂect a
biologically relevant beta HPV infection. Different studies have
focused on HPV-DNA positivity in the presence of a type speciﬁc
serological response (Proby et al., 2011), on high viral DNA loads
and/or multiple HPV types present (Neale et al., 2013), and/or the
presence in the SCC of a patient (Iannacone et al., 2014, 2012).
The beta HPV-DNA loads in plucked eyebrow hairs of immu-
nocompetent and immunosuppressed people span 7 orders of
magnitude (Weissenborn et al., 2012). Only the beta HPV loads
within the highest load decile are close to those observed in EV
patients, who are highly predisposed to SCC development
(Dell'Oste et al., 2009). The signiﬁcantly higher proportion of
samples from immunosuppressed individuals within the highest
load decile correlated with a more than 100-fold increased
incidence of cutaneous SCC (Weissenborn et al., 2012). In case
control studies, high beta HPV-DNA loads turned out to be
associated with cutaneous SCC (Neale et al., 2013). Odds ratios of
three were observed for having four or more beta HPV types in the
highest load tertile in plucked eyebrow hairs both in immuno-
competent Australians (95% CI: 1.11–8.09) and in immunosup-
pressed organ transplant recipients (95% CI: 1.35–7.62).
When the association between beta HPV type-speciﬁc seroposi-
tivity and SCC was stratiﬁed by DNA status of the same HPV type in
the SCC, signiﬁcant odds ratios of 3.4–3.8 were observed for HPV5,
HPV17, and HPV24 (Iannacone et al., 2012). When the association
between beta HPV type-speciﬁc DNA-positivity in eyebrow hairs and
SCC was stratiﬁed by DNA status of the same HPV type in the SCC,
the DNA prevalence in eyebrow hairs was signiﬁcantly higher among
cases compared to the controls for 11 of 25 genus beta types tested
(HPV5, -12, -19, -21, -24 of species beta 1, HPV22, -23, -38, -80 of
species beta 2, HPV75 of species beta 3, and HPV92 of species beta 4)
(Iannacone et al., 2014). Striking differences were observed in genus
beta type-speciﬁc DNA loads in plucked eyebrow hairs between
controls and SCC cases with DNA of the same HPV type in the tumor
(Fig. 1).
Taken together, recent case control studies have revealed weak
beta HPV type-speciﬁc associations of seropositivity, DNA preva-
lence and viral load with SCC. The meaning of the multiplicity of
infections and of viral load may provide some suggestion of a
dose–response relationship. These observed, although weak asso-
ciations are consistent with the potential for an etiological role for
a subset of the beta HPVs that can establish persistent infections
when combined with the growing appreciation for the potential
oncogenic activities encoded by the beta HPVs.
Oncogenicity of beta HPVs
The potential oncogenicity of the beta HPVs has been examined
using tissue culture transformation and immortalization assays as
well as transgenic mice. Several studies have compared various
beta HPV types with respect to the ability of their E6 and E7
proteins to transform rodent cells and to immortalize human
foreskin keratinocytes (HFKs) (Cornet et al., 2012; Massimi et al.,
2008). The oncogenicity of the beta HPVs however is perhaps best
demonstrated in transgenic mouse studies. The complete early
genome region of HPV8 or the E6 and E7 genes of HPV38 under
the control of the human keratin 14 promoter are oncogenic
(Schaper et al., 2005; Viarisio et al., 2011). HPV8 mice
spontaneously develop papillomas with varying degrees of epi-
dermal dysplasia and SCC develop in 6% of the mice without any
additional treatment with physical or chemical carcinogens
(Schaper et al., 2005). The HPV38 E6/E7 transgenic mice are highly
susceptible to two stage chemical carcinogenesis. Chronic UV
irradiation induced actinic keratosis-like lesions and subsequently
SCC (Viarisio et al., 2011).
HPV8 E6 (Marcuzzi et al., 2009) and HPV8 E2 (Pfefferle et al.,
2008) are independently able to induce skin cancer but with
marked differences in kinetics and histology. The HPV8 E6 mice
are a phenocopy of mice expressing the complete early genome
region, whereas the HPV8 E2 transgenic mice spontaneously
develop infundibular hyperplasia and acanthosis and the SCC
show an unusually high proportion of spindle cells. The rate of
tumor formation in E2 mice critically depends on E2 mRNA levels.
In three established lines the E2 mRNA levels differed in the ratio
6:3:1. The mice with the highest E2 mRNA levels developed
tumors in their ﬁrst year of life, only about 60% of mice with
medium mRNA levels developed tumors at the end of their second
year of life and only few animals of the line with the lowest mRNA
levels developed tumors at an age of more than two years. In the
HPV8 transgenic mice, a single UV irradiation or mechanical
wounding are highly efﬁcient triggers of papilloma development
within three weeks. HPV8 oncogene mRNA is induced about 10-
fold one day after UV irradiation (Hufbauer et al., 2010; Marcuzzi
et al., 2009). Even about one third of the E2 mice with the lowest
mRNA level developed skin lesions within three weeks after UV
irradiation and a highly aggressive SCC developed in one case
within 13 weeks (Pfefferle et al., 2008). Knocking down HPV8 E6
expression by tattooing gene speciﬁc siRNA delayed and partially
prevented papilloma development induced by wounding in the
course of tattooing (Hufbauer et al., 2010). These studies identify
enhanced HPV8 oncogene expression as a necessary prerequisite
for tumor development and suggest that oncogene expression
above a certain threshold can induce SCCs. In certain aspects, the
mouse model parallels the natural history of human beta HPV
infections. Despite continuous, low level expression of the onco-
genic transgene in all skin keratinocytes, it takes months and
sometimes more than one year to develop skin tumors without
experimental induction. Beta HPV infections in humans are
ubiquitous and acquired in early childhood but usually very well
controlled, persisting with low viral DNA loads. Extensive sun
exposure and impaired control following immunosuppression or
late in life due to immunosenescence are likely to induce onco-
gene expression and to allow transgression of a critical threshold
of mRNA levels in line with the increased risk of skin cancer. These
transgenic models establish the potential oncogenicity of speciﬁc
beta HPVs. As potential cancer viruses in humans the role of the
beta HPVs must however be at an initiation role since their
continued expression would not be required in human SCCs.
Oncogenic characteristics of the beta HPV E6 proteins
The high-risk alpha HPVs encode three oncogenes (E5–E7) of
which E6 and E7 are expressed in the associated cancers. Although
the beta HPVs do not encode an E5 gene, the beta E6 and E7 genes
are structurally quite similar to their alpha genus counterparts.
Recent proteomic studies have highlighted similarities and differ-
ences between the alpha and beta genus E6 and E7 proteins.
The E6 proteins have been implicated in the potential carcino-
genic activities of the beta HPVs. The skin cancers observed in EV
patients mostly occur in sun exposed areas suggesting a synergism
between the beta HPV infections and the carcinogenic effects of
UV light. An important contribution to SCC development could
come from interference of the beta E6 proteins with DNA repair
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and UV-induced apoptosis (Giampieri and Storey, 2004; Jackson
and Storey, 2000; Underbrink et al., 2008), allowing keratinocytes
with UV-induced mutations to survive and progress to carcinomas.
The E6 proteins of HPV5, -8, -20, -22, -38, -76, -92, and -96 have
been reported to target the proapoptotic protein Bak for degrada-
tion and thus to prevent UV-induced apoptosis (Jackson and
Storey, 2000; Underbrink et al., 2008). E6 of HPV5 and HPV8 bind
p300 resulting in delayed ATR activation (Muller-Schiffmann et al.,
2006; Wallace et al., 2012). The delayed ATR activation leads to
delayed accumulation of p53, reduced G1 arrest, the increased
likelihood of double strand breaks, and delayed repair of UV-
damaged DNA. The beta HPV E6 proteins vary however in their
effects on p53 stabilization following DNA damage (White et al.,
2014) and several (HPV5, -8 and -38) have been shown to inhibit
its stabilization following DNA damage (Wallace et al., 2014).
Several of the beta E6 proteins have been shown to induce
telomerase activity resulting in life span extension (Bedard et al.,
2008; Gabet et al., 2008). These functions would support a
potential role for the beta HPVs in the initiation of SCC, but not
be required for tumor maintenance.
Systematic proteomic studies of the HPV E6 proteins from both
the alpha and beta genera have revealed that the alpha HPV E6
proteins are bound to the ubiquitin ligase E6AP whereas the beta
HPV E6 proteins are bound to the transcriptional co-activator
mastermind (MAML1) (White et al., 2012a). MAML1 is a transcrip-
tional regulator that is involved in several cell signaling pathways
and the result of the E6–MAML interaction is the inhibition of
Notch mediated transcription (Brimer et al., 2012; Meyers et al.,
2013; Tan et al., 2012). Although Notch functions as an oncogene in
some T-cell leukemias, Notch acts as a tumor suppressor in
squamous epithelial cells (McElhinny et al., 2008; Wu et al.,
2000). Notch has been found often to be mutated in head and
neck cancers (Agrawal et al., 2011; Stransky et al., 2011). Notch has
a role in keratinocyte differentiation; its activation leads to
induction of the cell cycle inhibitor p21 as well as the expression
of keratinocyte cellular differentiation markers (Rangarajan et al.,
2001; Restivo et al., 2011). In addition to binding MAML1, most of
the beta E6 proteins are also found in complex with several
MAML1 binding partners including Notch1 and RBPJ (Rozenblatt-
Rosen et al., 2012; White et al., 2012a).
The genus-speciﬁc interactions of the alpha genus E6s with
E6AP and the beta genus E6s with MAML1 respectively involve a
very similar alpha helical LXXLL binding motif in each of these
cellular proteins (Brimer et al., 2012; Chen et al., 1995; Nuber et al.,
1996; Tan et al., 2012). This LXXLL motif is believed to be engaged
by a ﬂexible linker region on E6 located between the two globular
domains that compose the N- and C-terminal halves of E6s
(Nomine et al., 2006).
Aside fromMAML1 and other Notch associated components, no
other cellular proteins complex with all of the beta E6 proteins
(White et al., 2012a). A number of other cellular proteins have
been shown to bind the beta E6 proteins, but in each case only a
subset of E6s (White and Howley, 2013). For instance, several
studies have shown that E6 from HPVs 5, 8, 20 and 25 (all from
genus beta and species 1) bind to the acetyltransferases CBP and
p300 (Howie et al., 2011; Rozenblatt-Rosen et al., 2012; White et
al., 2012a). E6 from HPV38 (genus beta and species 2) binds p300
much weaker than E6 from species 1 HPV types (Howie et al.,
2011; Muench et al., 2010). In addition, several of the beta E6s
(HPV38 and 92) bind and stabilize p53 (White et al., 2012a),
however in response to DNA damage, HPV 38 is reported to
attenuate p53 signaling (Wallace et al., 2014). Human keratinocyte
cell lines expressing various E6 proteins have been proﬁled for
their transcriptional responses to DNA damage and the beta E6
proteins vary in their ability to block such responses (White et al.,
2014). Finally, HPV5 E6 has been to bind SMAD3 and repress TGFβ
signaling (Mendoza et al., 2006). These observed differences in
biological responses combined with the differences among E6
cellular binding partners indicate that the beta HPVs are not
homogeneous with regard to their biologies or the pathologies
with which they are associated.
Oncogenic characteristics of the beta HPV E7 proteins
Results from systematic proteomic studies of the HPV E7 proteins
revealed patterns of cellular binding proteins that were quite
different from those seen with the E6 proteins. Common binding
partners were seen for E7 proteins of both the alpha and beta genera
suggesting that functions are conserved among the various E7
proteins. The beta E7 proteins, like the alpha E7 proteins, all bind
pRB1. The alpha and beta E7 proteins all contain an LXCXE motif
responsible for binding to pRB1 and the related “pocket proteins”
pRBL1 (p107) and pRBL2 (p130) (White et al., 2012b). In addition to
the pRB family of pocket proteins, the pRB E2F partners were
observed binding to many of the E7 proteins. There have also been
a number of speciﬁc studies of the beta HPV E7 proteins with pRB.
For instance, HPV38 E7 has been shown to bind pRB with a similar
efﬁciency as HPV16 E7 and promote pRB destabilization (Caldeira et
al., 2003). HPV8 E7 binds to pRB only weakly but is nevertheless able
to inactivate pRB to deregulate G1/S transition control (Akgül et al.,
2007). It is interesting to note in this context that UV-induced
oncogene expression in HPV8 transgenic mice was associated with
an upregulation of the oncogenic miRNA 106a and a downregulation
of its known cellular target pRB (Hufbauer et al., 2011).
In addition to pRB all the alpha and beta HPV E7 proteins bind
UBR4, also known as p600 (White et al., 2012b). UBR4 was initially
shown to bind E7s from HPV16, 6b, and 11 as well as from the
bovine papillomavirus (BPV1) (DeMasi et al., 2005; Huh et al.,
2005). UBR4 contains a UBR box, a motif that is common to proteins
involved in the N-end rule-mediated degradation of proteins
(Tasaki et al., 2005, 2009), and it is suspected that it is a functional
E3 ubiquitin ligase that functions in an N-end rule pathway. The
conservation of the UBR4 interaction with E7s across several PV
genera, suggests this interaction is likely to mediate important PV-
related functions that have not yet been discovered. In addition, all
E7's complex with KCMF1, another putative E3 ubiquitin ligase that
is a binding partner of UBR4 (White et al., 2012b).
Another HPV E7 cellular binding partner shared across the
alpha and beta genera is PTPN14, a non-receptor tyrosine phos-
phatase (White et al., 2012b). PTPN14 has been implicated in
density-dependent cell growth (Wang et al., 2012). PTPN14 binds
YES1, a regulator of Hippo signaling, and PTPN14 negatively
regulates YES1 when cells are at high density. Nothing is known
yet about the consequences of E7 binding to PTPN14 and role of
this binding in PV biology, but E7/PTPN14 binding suggests the
possibility that E7 may affect the Hippo pathway.
Concerning the potential oncogenic role of the beta E7s, it is
noteworthy that HPV8 E7 upregulates the expression of the
invasion-promoting MT1-matrix metalloproteinase (Akgül et al.,
2005; Smola-Hess et al., 2005) and causes invasion of keratino-
cytes into the dermis of organotypic keratinocyte cultures (Akgül
et al., 2005). E7 of HPV5, -8, and -20 increases the number of stem
cell-like keratinocytes, deﬁned by high expression of surface
markers CD44 and EpCAM, with increased clonogenicity and
strongly positive in tumor sphere assays (Hufbauer et al., 2013).
Oncogenic characteristics of the beta HPV E2 proteins
As noted above, the most compelling evidence for the onco-
genicity of E2 derives from transgenic mouse experiments in
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which HPV8 E2 is expressed from the human keratin 14 promoter
(Pfefferle et al., 2008). The E2 gene is highly conserved among all
papillomaviruses and has key roles in the regulation of virus
transcription, viral DNA replication and in plasmid maintenance
in dividing cells (Howley et al., 2013). The C-terminal portion of E2
is conserved and consists of a dimerization and sequence speciﬁc
DNA-binding domain that recognizes cognate sites within the
non-coding region upstream of the E6 and E7 genes and adjacent
to the origin of DNA replication. The N-terminal portion of E2 is
also conserved and binds the viral E1 helicase protein to help
recruit it to the origin to initiate viral DNA replication. The
conserved N-terminus also binds a number of cellular proteins
that are involved in mediating E2's functions. Proteomic studies
have deﬁned many binding partners for the alpha and beta genus
E2 proteins that are involved in transcription, cell cycle control,
RNA processing and apoptosis, among other processes (Muller et
al., 2012). The oncogenicity of HPV8 E2 is not yet well understood
but could involve the transcriptional regulation of a cellular gene
or genes or it could be the consequence of binding to a speciﬁc
cellular protein or complex.
Summary: a role for the beta HPVs in keratinocyte carcinoma
The consideration of an etiologic role for the beta HPVs in KCs
has been framed largely by the knowledge of the mechanisms by
which the alpha genus HPVs cause cancer in which the expression
of the viral oncoproteins is required for the maintenance in
addition to the initiation of the cancers. Clearly that is not the
case for the KCs in which viral transcription is not detected and
viral genome load in the cancers is signiﬁcantly less than one copy
per cell. Given the ubiquitous nature of the beta HPVs, epidemio-
logic studies have proven difﬁcult. The increase of KCs in immu-
nosuppressed patients is highly suggestive of a viral etiology to the
cancers (Wieland et al., 2014). However, a role for these viruses in
KCs must be at the early stages of cancer formation; the viruses
must participate in cancer initiation.
A number of studies have established the potential oncogeni-
city of the viruses and their individual genes in transgenic mice as
well as in tissue culture models. Furthermore detailed studies of
the viral E6 and E7 genes provide mechanistic insights as to how
the beta HPVs might participate in initiating carcinogenic pro-
cesses. The increased risk of KCs in sun exposed areas in patients
with EV and in immuno-suppressed patients suggests a synergism
between DNA damage from UV light and a mechanistic contribu-
tion from the beta HPVs. Several studies with speciﬁc beta HPV
E6s have shown that they can block DNA damage pathways and
inhibit apoptosis in mechanisms that appear to involve E6 binding
p300 and/or CBP. The beta E6 proteins also target MAML1, a
necessary component of Notch signaling, to inhibit Notch signaling
in keratinocytes. Notch plays a role in keratinocyte differentiation
and functions as a tumor suppressor gene in epithelial cells.
Therefore, inhibiting Notch signaling in keratinocytes can inhibit
differentiation and perhaps contribute to the continued prolifera-
tion of the HPV infected cell. Through targeting p300 as well as
MAML1 and Notch signaling, E6 could function in cancer initiation
by allowing a beta HPV infected cell to accumulate the genomic
mutations necessary to progress to cancer. The beta HPV E7s also
have oncogenic activities. Its binding partners are similar to those
of the alpha genus HPVs, and include the pRB family of pocket
proteins that are well established as tumor suppressor genes. They
also include binding proteins that have been less well studied with
regard to their roles in papillomavirus host cell interactions,
including UBR4 and PTPN14 (White et al., 2012b).
A major unanswered question assuming the beta HPVs indeed
do have an etiologic role in the initiation of KC is why the presence
of the viral genome and its expression are not detectable in the
cancers. Is there active selection against the beta HPVs? If so, is
this selection immunological, or is continued expression of the
virus toxic to the cell? One trivial explanation would be that the
beta HPV DNA is lost because its expression is not required for
maintenance of the cancer and there is therefore no selection for
its persistence. In contrast to the alpha HPV-positive anogenital
cancers integration of beta HPV DNA into the cellular genome
appears to occur extremely rarely in EV-KC. In one EV-patient
HPV5 DNAwas not yet integrated in the primary cancer but only in
a metastasis (Yabe et al., 1989). Therefore if the major contribution
of the beta HPVs to KC is at the initiation stage and viral functions
are not required for cancer maintenance since the malignant
growth of cancer cells is driven by the accumulated DNA muta-
tions, there would be no selective pressure to maintain the
viral DNA.
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